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The physicochemical hallmarks of particulate immunopotentiators play a pivotal role with regards to their
adjuvanticity in vivo. These properties have not been fully characterised in the case of MCT®, an amino
acid-based adjuvant used as an alternative to aluminium salts in subcutaneous allergy immunotherapy
(SCIT). This study presents a full characterisation of MCT® and in a preliminary capacity reveals how
parameters, speciﬁcally particle size, might inﬂuence the recognition of MCT® by antigen presenting
cells (APCs) in vitro. Light microscopic analysis demonstrated that MCT® was composed of highly
crystalline needles, the majority of which exceeded 10 mm in length under physiological conditions
(median size – 20.8 mm). While the substantial length of crystals presented a signiﬁcant barrier to cellular
recognition and uptake, isolated incidences of perpendicular recognition were observed owing to the
smaller comparative width of crystallites (median size – 2.8 mm). This appeared to allow a small
proportion of material to be ingested both fully and partially by THP-1 macrophages, although further
studies are required to unequivocally conﬁrm this observation. Preferential recognition of needle tips
also favoured the direct presentation of antigen to immune cells as proteinaceous adsorption appeared
to be isolated to these regions. Furthermore, the data herein provide valuable insights into the
mechanisms surrounding how this adjuvant potentiates an immunological response following
administration.Introduction
Modulation of the mammalian immune response towards
allergens via the administration of subcutaneous allergy
immunotherapy (SCIT) has proven an eﬀective preventative
strategy in the treatment of chronic hypersensitivity. The
success of SCIT in this capacity has been attributed in part to its
ability to upregulate regulatory T cell (Treg) activity at early
junctures post-vaccination, which facilitates both allergenic
tolerance and T-cell homeostasis (see review1). Indeed, admin-
istration of SCIT has induced prolonged suppression of
allergen-specic IgE and Th2 dominant proles via such
mechanisms in both asthmatic individuals2–4 and those exhib-
iting severe reactions to Hymenoptera venom.5–9 As a result,
SCIT remains an essential clinical regimen used to directly
regulate and modify the aberrant immunological responses
observed during allergic episodes.
In order to enhance the eﬃcacy, longevity and tolerability of
SCIT, it is oen necessary to include an adjuvant onto which
antigens are adsorbed. While these compounds are notaboratories, Keele University, Keele,
keele.ac.uk
tion (ESI) available. See DOI:
hemistry 2019expected to be antigenic in their own right, their modulatory
and stimulatory inuence upon immunological events
following antigenic challenge is well documented.10,11
Aluminium salts represent the quintessential choice of adju-
vant for inclusion within SCIT vaccines12 and are present in ca.
75% of all formulations intended for this purpose.13 Their
economic fabrication14 and perceived safety15 have contributed
to their sustained popularity; however, the increasing incidence
of aluminium-associated adverse reactions observed in indi-
viduals receiving SCIT casts some doubt upon the latter asser-
tion.16–20 In fact, the development of localised complications
during the course of SCIT administration, which included
pruritic nodules,21 urticaria,22 and granulomas19 contributed to
an increase in patient non-compliance and premature termi-
nation of the treatment protocol (ca. 21% cases).23 Aluminium
adjuvants are also particularly inept at inducing cell-mediated
responses in murine models instead skewing immunological
proles towards a predominantly Th2 response.24–26 Further-
more, the enhanced humoral responses potentiated by
aluminium salts in vivo, as characterised by heightened levels of
serum IL-4 and IL-13 27 appears to be counter-intuitive with
regards to the mediation of allergic immunopathology. In
conjunction, these factors emphasise the requirement for the
development of safer more eﬃcacious alternatives.RSC Adv., 2019, 9, 24505–24518 | 24505
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View Article OnlineOne such promising candidate is the amino acid L-tyrosine
(L-tyr), a proprietary formulation manufactured under the
registered trademark micro-crystalline tyrosine (MCT®). The
immunotherapeutic potential of MCT®-allergen adsorbates in
the treatment of allergic rhinitis, for example, has been recently
demonstrated in clinical trials using the Pollinex® Quattro
short-course administration protocol.28,29 The eﬃcacy of MCT®
as an adjuvant within prophylactic vaccines against inuenza30
and malaria31 has also been investigated. L-tyr is already present
within the human subcutaneous interstitial milieu at
a concentration of ca. 54 mM (10 mg mL1)32 and as such appears
to be reasonably well tolerated both systemically and locally at
doses < 40 mg mL1.33,34 The diminutive solubility of L-tyr in
aqueous media at physiological pH (ca. 0.45 mg mL1) also
facilitates a controlled and prolonged release of antigenic
material at the site of injection, whilst limiting the bio-
persistence of the adjuvant itself.33,35 The transient nature of L-
tyr in the interstitial space is recognised as an important factor
governing the safety of this material, minimising the risk of
delayed hypersensitivity reactions, granuloma and nodule
formation.35
How particulate adjuvants facilitate the polarisation and
potentiation of the immune response during vaccination is yet to
be fully elucidated; however, postulated mechanisms include the
induction of pro-inammatory cytokine secretion through activa-
tion of the NALP-3 inammasome,36–39 depot formation35,40,41 and
improved antigenic cross-presentation through enhanced recog-
nition and uptake by antigen presenting cells (APCs).42–46 Recent
literature has highlighted the importance of particulate phys-
icochemistry with regards to the subsequent biological activity of
adjuvants administered as colloidal suspensions (see review47).
Properties which signicantly inuence the adjuvanticity of such
materials include solid-state structure, particle size, particle shape
and zeta potential.14,47 The hydrodynamic particle size of adjuvants
is particularly important with regards to the recognition of such
material by immunocompetent cells at the site of injection,
a precursor to particulate uptake and cellular translocation to the
draining lymph nodes.47 In order to increase the understanding of
the mechanisms by which MCT® promotes desensitisation in
SCIT, this is the rst study to fully characterise the physicochem-
ical properties of MCT® and examine their inuence, especially
that of particle size, upon the cellular recognition of this adjuvant
in vitro.Materials and methods
Adjuvants and chemicals
MCT® stock solutions containing ca. 40 mg mL1 L-tyr in
buﬀered saline (0.5% w/v phenol) were provided by Allergy
Therapeutics (Worthing, UK) and stored at 4 C upon receipt. L-
tyr standard ($98%) and ovalbumin lyophilate (OVA) ($98%)
were both purchased from Sigma-Aldrich, UK.Structural characterisation of MCT®
In preparation for structural characterisation, the aqueous
phase of MCT® was removed via ltration through24506 | RSC Adv., 2019, 9, 24505–24518a polycarbonate lter membrane (pore size-50 nm, Poretics
Corp., US) using a reduced-pressure ltration system (Millipore,
UK). The solid material collected on the membrane was
removed and dried in an incubator at 37 C for 72 hours. Aer
this duration samples were ground to a ne powder and stored
in a calcium chloride desiccator under vacuum until required.
FT-IR spectra were collected between 4000 & 600 cm1 using
a Thermo Nicolet FT-IR spectrometer with an ATR germanium
crystal attachment. Atmospheric background scans were per-
formed in the absence of sample within the experimental range
before eachmeasurement and subtracted from subsequent data
sets. For each experimental sample, 64 scans were collected in
order to enhance the signal to noise ratio and thus spectral
quality. Peak assignments and ATR correction algorithms were
applied to raw spectra using OMNIC soware prior to
presentation.
XRD patterns were obtained between 2q values of 10 and 50
at an interval of 0.5 using a Bruker D8 Advance powder X-ray
diﬀractometer (CuKa radiation – 0.154 nm).
TGA analysis was performed over a temperature range of 20–
800 C (ramp 10 C per minute) using a STA 1500 TGA/DSC heat-
ux simultaneous thermal analyser.
TEM was performed using a JEOL1230 transmission electron
microscope (operating voltage – 100 kV) with a SIS Megaview III
digital camera attachment. Samples were prepared upon
formvar/carbon coated 200 mesh copper grids (Agar Scientic,
UK) according to a procedure adapted fromMold et al.48 Briey,
grids were immersed in sample beads (30 mL) containing 2 mg
mL1 MCT® in UPW for 2 minutes, wicked to remove excess
sample and allowed to dry for 24 h prior to visualisation. Grids
stained using 2% uranyl acetate (70% v/v EtOH) were subjected
to an additional immersion (30 s), wicking and rinse stage prior
to dehydration.
Preparation of vaccines
A stock solution of L-tyr (ca. 40 mg mL1) was prepared through
the addition of physiological saline (0.9% NaCl in UPW, pH 7 
0.1) to L-tyr powder (0.8 g) and stored at 4 C until required.
Model vaccines were prepared via the addition of RT equili-
brated stockMCT® or L-tyr dropwise to physiological saline.Where
a model antigen was included in the preparation, MCT® or L-tyr
was added to physiological saline containing 70 mg mL1 OVA
(1 : 10 protein to adjuvant ratio). Formulations were adjusted to
pH 7  0.1 using sodium hydroxide (0.1 M) and exposed to
constant agitation (ca. 500 rpm) at RT for 1 h before analysis or
inclusion within subsequent experimental procedures.
Particle size determination
Size-exclusion ltration. In preparation for the determina-
tion of particle size via tyrosine quantication, model vaccines
containing MCT® or L-tyr were subject to syringe ltration using
47 mm hydrophilic PVDF and PES membranes with nominal
pore sizes of 5 & 0.1 mm respectively (Merck Millipore, UK). To
increase the accuracy of the data collected, equal volumes of
whole vaccine samples were passed through each lter (ca. 3
mL) and collected for analysis.This journal is © The Royal Society of Chemistry 2019
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View Article OnlineFluorescence quantication of tyrosine. Tyrosine quanti-
cation was performed using a PerkinElmer LS-55 uorescence
spectrometer at an excitation wavelength of 273 nm. Calibration
curves were performed prior to each set of measurements using
a series of L-tyr standard solutions ranging from 0.625–40 mM,
which were prepared through serial dilution of an L-tyr stock
solution (200 mM in UPW) in the relevant experimental diluent.
Emission spectra were collected between 250 & 700 nm and the
concentration of tyrosine in samples was derived from readings
taken at ca. 307 nm (l max). Experimental values were derived
from the averages of three individual measurements made per
sample replicate where the RSD of these values #10%.
Prior to commencing the analysis of vaccine ltrates con-
taining protein, OVA only controls (70 mg mL1 OVA in saline)
were performed in order to negate any uorescence signal
originating from the antigen.
Light microscopy. Measurements of individual particles
within MCT®-adjuvanted vaccines were made using an
Olympus BX50 uorescence microscope. Light images were
taken at a magnication of 200 and particle measurements
were performed within the Cell D soware. Prior to visual-
isation, MCT® + OVA samples were stained with Congo red
solution (5 mg mL1 in 50% v/v EtOH) in order to highlight the
antigenic material present within the sample.
Zeta potential measurements. The zeta potential of indi-
vidual samples at RT was measured via electrophoretic light
scattering (ELS) using a Malvern Zetasizer Nano ZS. Samples
were housed within polystyrene folded capillary cells equipped
with gold plated beryllium/copper electrodes for the duration of
the measurement. A total of ve measurements were made per
sample replicate.
Solubility in model interstitial uid (MIF). The MIF buﬀers
used in solubility experiments incorporate a combination of
biologically relevant constituents (Table S1†) adapted from
studies attempting to elucidate the composition of human
interstitial uid.32,49,50 Following preparation, each MIF formu-
lation was adjusted to pH 7.4  0.05 using sodium hydroxide
and stored at 4 C prior to use.
MIF (0.4 mL) was aliquoted into Eppendorf tubes and
allowed to reach a temperature of 37 C before the addition of
vaccines (0.6 mL) which contained ca. 10 mg mL1 MCT® or an
equivalent phenol only control. Samples were held under
constant agitation (ca. 500 rpm) for the duration of the experi-
ment and kept at 37 C using a water bath.
Supernatants were collected at T ¼ 1, 2, 3, 4, 24, 48, 72 &
168 h and analysed for soluble tyrosine content by uorescence
spectroscopy. Supernatants were obtained through centrifuga-
tion of the whole sample at 1 5000 g for 5 minutes. A total of
0.5 mL of the supernatant was carefully aspirated for analysis
and the volume removed was replaced with fresh MIF (37 C) at
each analytical time point.Cellular experiments
Maintenance of THP-1 parent cultures. THP-1 cells (ECACC
88081201), originally derived from a one-year old male with
acute monocytic leukemia, were obtained from Public HealthThis journal is © The Royal Society of Chemistry 2019England (PHE), UK as a growing culture. Cultures were main-
tained using RPMI 1640 medium (GlutaMAX™, Thermo Fisher
Scientic, UK) supplemented with HEPES (25 mM), gentamicin
(100 mg mL1) and heat inactivated FBS (10% v/v, US certied).
This medium will hereaer be referred to as R10 medium.
Parent cultures were maintained at 37 C within an atmosphere
containing 5% CO2 and additional humidity. Cell passage was
performed when cultures reached a density of ca. 106 cells per
mL.
Diﬀerentiation of THP-1 cells. Prior to performing the
diﬀerentiation protocol, the viability of THP-1 cells was
conrmed using the trypan blue exclusion test. The procedure
used herein was adapted from that optimised by Lund et al.51
Briey, THP-1 cells were seeded into 24 or 96 well plates at
a density of 40 000 cells per well and stimulated with 25 nM
PMA in R10 medium for a duration of 48 h. Cells in 24 well
plates were cultured onto 13 mm round coverslips which had
been sterilised in 70% v/v EtOH before use. The PMA was then
removed from the wells and the cells were allowed to rest for
a further 24 h in fresh R10medium before treatment. Successful
diﬀerentiation of THP-1 cells was conrmed using light
microscopy (Fig. 10A).
Cellular uptake of MCT. Cells were treated in 24 well plates
with vaccines containing 2 mg mL1 MCT® and le to incubate
for 1 h at 37 C (5% CO2). Cells were then washed twice with PBS
(1) and xed using paraformaldehyde (0.22 mm ltered, 4% w/
v in saline supplemented with 25 mM PIPES) for 15 minutes.
Fixed cells were then washed twice more with PBS (1) and the
coverslips were mounted onto slides using a small amount of
Fluoromount™ aqueous mounting media (Sigma-Aldrich, UK).
The uptake of MCT® by diﬀerentiated THP-1 cells was subse-
quently assessed under polarised light using light microscopy.
Determination of cell viability. The viability of diﬀerentiated
THP-1 cells in the presence of MCT® containing vaccines was
determined using the Presto blue colorimetric assay (Thermo
Fisher Scientic, UK). Cells were treated in triplicate groups
with 0, 0.3, 0.7, & 2 mgmL1 MCT® in saline for 1 h at 37 C (5%
CO2). Wells containing no cells were also treated with MCT® in
order to assess the individual inuence of this adjuvant upon
the assay. Following incubation, cells were washed twice with
PBS (1) and incubated for a further 24 h in the presence of
Presto blue reagent (1 : 10 Presto blue reagent : R10 medium).
The average of each triplicate set of conditions was derived from
the absorbance measured at 570 nm following a background
correction at 600 nm using a TECAN M200 innite pro plate
reader.Statistical analysis
Statistical signicance was determined using GraphPad Prism
v.7 soware, where a p value of #0.05 was indicative of
a signicant comparison. Before comparisons were made, the
normality of datasets was analysed using a Shapiro–Wilk test.
Multiple independent comparisons were made using an ANOVA
followed by Tukey post hoc tests and equivalent time dependent
comparisons were performed using a Friedman test followed by
Dunn post hoc tests. Two-tailed unpaired t-tests were used toRSC Adv., 2019, 9, 24505–24518 | 24507
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View Article Onlineassess the signicance of pairwise comparisons. Comparisons
between particle size distributions (PSDs) were made using
a Kolmogorov–Smirnov test.Results
FTIR
The FTIR spectral characteristics of dehydrated MCT® were in
good agreement with those obtained for the L-tyr standard
(Fig. 1). The absorption band observed at 3199 cm1 was
attributed to the symmetric stretch of NH3
+. Aromatic and
aliphatic CH2 vibrational modes were detected in the regions
3106–3013 and 2960–2503 cm1 respectively. NH3
+ asymmetric
bending vibrations were characterised by intense adsorption
bands at 1607 & 1588 cm1 and the in-plane aromatic CH2
bending mode located at 1513 cm1. Both vibrational and
bending modes specic to aliphatic CH2 moieties (dCH2 and
uCH2) and those of the phenolic ring (nC–C & dCH) were
observed at 1454 & 1363 cm1 and 1435, 1331, 1156 and
1099 cm1 respectively. A single band synonymous with that
expected for the symmetric stretch of the phenolic C–O bond
was identied at 1246 cm1. The region < 1000 cm1 was
populated by several wagging modes most prominently that of
the aromatic C–H bond (841 and 740 cm1), the amino N–H
bond (803 cm1) and the carboxylic OH bond (651 cm1).XRD
The unrened powder diﬀraction pattern of MCT® corre-
sponded to that of L-tyr. The two diﬀractograms exhibitedFig. 1 FTIR spectra of MCT® (A) and L-tyr (B) determined over the rang
24508 | RSC Adv., 2019, 9, 24505–24518a single phase of well-resolved and narrow Bragg reections in
the region spanning 10–50 2q (Fig. 2).
TGA
TGA curves of MCT® and L-tyr were characteristically reminis-
cent exhibiting a total weight loss of 95.6 and 88.7% respectively
up to 800 C and thermal stability up until 289 C (Fig. 3).
Thermographs demonstrated no signicant loss of mass <
200 C. Decomposition commenced above 289 C and was
marked by a single signicant phase transition, which
accounted for a total weight loss of 56.5 and 40.0% respectively.
The remaining mass (39.1 and 49.1% respectively) was elimi-
nated gradually above 317 C.
TEM
MCT® presented as a heterogeneous collection of crystalline
needles, whose sizes ranged from ca. 4 to >10 mm in length
(Fig. 4). Larger needles were composed of several smaller rod-
like entities each exhibiting a similar structural orientation.
The presence of void spaces and crevasses within clustered
formations was also observed (Fig. 4A), although the latter was
oen isolated to the peripheral areas/tips of the structure
(Fig. 4C).
Particle size determination
Fluorescence quantication of populations < ca. 5 mm vs.
adjuvant concentration. Preliminary studies revealed that
contributions from the phenol additive within MCT® vaccines
precluded the accurate quantication of soluble tyrosine within
ltrates obtained from formulations containing $10 mg mL1e 4000–600 cm1.
This journal is © The Royal Society of Chemistry 2019
Fig. 2 Unreﬁned powder diﬀraction patterns of MCT® (A) and L-tyr (B) determined over the range 10–50 2q.
Fig. 3 TGA thermographic proﬁles of MCT® (A) and L-tyr (B) deter-
mined from 20–800 C.
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View Article OnlineMCT® (data not shown). In order to eliminate interference of
this nature, MCT® was replaced by L-tyr in all subsequent
uorescence quantication experiments.This journal is © The Royal Society of Chemistry 2019A substantial elevation in the recovery of L-tyr particulates
>ca. 5 mm in size was evident as the concentration of the adju-
vant increased beyond that of its average solubility in saline
(0.39  0.03 mg mL1) (Fig. 5A). Indeed, at a concentration of
0.3 mg mL1, L-tyr was present in an entirely soluble format
within the vaccine preparation as demonstrated by the near
complete recovery observed <ca. 0.1 mm (0.28  0.01 mg mL1,
99.6%). Above this threshold, the amount of tyrosine <ca. 5 mm
in size remained fairly consistent (0.39  0.01–0.42  0.01 mg
mL1), although the majority of tyrosine detected was below
<0.1 mm and thus considered soluble (0.33  0.003–0.42 
0.01 mg mL1) (Fig. 5B). Furthermore, particles between 5–0.1
mm were present in trace amounts in all vaccines analysed (1 
1–5  2 mg mL1), only increasing in abundance in ltrates
obtained from the highest concentration used in this study (79
 11 mg mL1) (Fig. 5C).
Fluorescence quantication of populations < ca. 5 mm:
MCT® + OVA. A slight but statistically insignicant increase in
the abundance of particles >ca. 5 mm in size was noted in
ltrates obtained from vaccines containing OVA vs. that derived
from adjuvant only preparations (0.39 0.03 vs. 0.33 0.01, P¼
0.12) (Fig. 6A). The recovery of soluble tyrosine also decreased
(0.32  0.01 vs. 0.38  0.01, P < 0.0001) (Fig. 6B) and was
accompanied by the complete abolition of particles between 5 &
0.1 mm in size (Fig. 6C).
Quantication of populations > ca. 5 mm. Microscopy
derived PSDs revealed that particulate lengths in saline ranged
from 7.3–95.5 mm in length, with a median size of 37.5 mm
(Fig. 7A). Crystalline widths were signicantly smaller (P <
0.0001) spanning a range of 1.4–8.5 mm in size, with a median
value of 4.9 mm (Fig. 7B).
The addition of a model antigen to the vaccine milieu
induced a signicant reduction in the dimensions of MCT®
crystals relative to that observed for MCT® alone (P < 0.0001).RSC Adv., 2019, 9, 24505–24518 | 24509
Fig. 4 TEM images of MCT® prepared at a concentration of 2 mg mL1 in UPW alone (A) or in the presence of 2% uranyl acetate staining (B, C
and D). Images were taken at a magniﬁcation of 5, 20, 15 and 12k respectively and scale bars represent 5, 1 and 2 mm respectively.
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View Article OnlineWhile the span of the distribution generated for length was
comparable to that obtained for MCT® alone (4.8–91.9 mm),
both the interquartile range (IQR) and median size had shied
to favour lower values (11.3–31.1 mm and 18.0 mm respectively).Fig. 5 Quantiﬁcation of L-tyrosine in ﬁltrates obtained from vaccines con
and (B) represent the particulate recovery > ca. 5 mm and <0.1 mm (soluble
0.1 mmand panel (D) highlights the relative percentage contribution of eac
the measurement where n ¼ 5. Data were analysed for statistical signiﬁc
24510 | RSC Adv., 2019, 9, 24505–24518The width of particulates in the presence of OVA also appeared
smaller than those within preparations containing MCT® alone
(P < 0.0001). Both the span and median size had decreased in
this case to 1.2–5.7 mm and 2.7 mm respectively.taining 0.3–40mgmL1 L-tyr formulated in saline, pH 7 0.1. Panels (A)
) respectively. Panel (C) shows the particulate recovery between 5 and
h fraction to the whole vaccine. Error bars are representative ofSD of
ance using an ANOVA followed by Tukey post hoc tests.
This journal is © The Royal Society of Chemistry 2019
Fig. 6 Quantiﬁcation of L-tyrosine in ﬁltrates obtained from vaccines containing L-tyr (0.7 mgmL1) and L-tyr + OVA (0.7 mgmL1 + 70 mgmL1)
formulated in saline, pH 7  0.1. Panels (A) and (B) represent the particulate recovery > ca. 5 mm and <0.1 mm (soluble) respectively. Panel (C)
shows the particulate recovery between 5 and 0.1 mm and panel (D) highlights the relative percentage contribution of each fraction to the whole
vaccine. Error bars are representative of SD of the measurement where n ¼ 5. Data were analysed for statistical signiﬁcance using a two-tailed
unpaired T-test.
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View Article OnlineIntroduction of MCT® into culture medium prompted
a substantial reduction in the length of crystallites vs. that
observed in saline, as demonstrated by the decrease in IQR and
median particle size (14.9–26.3 mm and 20.8 mm respectively, P <
0.0001); however, the terminal values of the distribution
remained similar in magnitude (4.1–107.9 mm). A moderate
reduction in the d50 and IQR values obtained for particulate
width was also observed under these conditions (2.8 mm and
2.3–3.4 mm respectively, P < 0.0001). Null signicance was found
when distributions generated for crystallite length in the pres-
ence of OVA and R10 medium were compared (P ¼ 0.53);
however, the latter prompted a slight decrease in crystallite
width which signicantly altered distribution parameters (P <
0.0001).
Zeta potential measurements. Within physiological saline,
vaccines formulated using low concentrations of MCT®
exhibited a negative zeta potential (9.2  0.6 mV) (Fig. 8).
Incorporation of antigenic material into the vaccine induced
a diminutive but signicant reduction in zeta potential (13.4
 1.0 vs. 9.2  0.6 mV, P < 0.0001).
Solubility of MCT® in MIF. During an incubation period of 1
week within a basal MIF medium (MIF base), a total of 2.87 
0.07 mg mL1 (ca. 47%) soluble tyrosine was liberated from the
MCT® vaccine depot (Fig. 9A). This value was signicantly lower
than that obtained inMIF containing phosphate (MIF PO4) (3.17
0.07 mg mL1, P ¼ 0.003) but comparable to that observed in theThis journal is © The Royal Society of Chemistry 2019presence of both phosphate and citrate ions (MIF cit.) (3.04 
0.08 mg mL1, P ¼ 0.14) (Fig. 9B and C respectively). The average
solubility of MCT® over the period of study was the highest inMIF
containing phosphate (0.40 mg mL1) and the lowest in MIF base
(0.36 mg mL1). Only introduction into MIF PO4 and MIF cit.
prompted a signicant initial elevation in the solubility of MCT®
relative to that observed in saline following 1 h at 37 C (0.46 
0.03 mg mL1 and 0.46  0.01 mg mL1 respectively vs. 0.40 
0.004 mg mL1, P ¼ 0.03). Linear regression analysis demon-
strated that the rate of solubilisation of MCT® over the rst 4 h in
MIF was positively inuenced by the presence of both phosphate
and citrate (P ¼ 0.02 and 0.008 respectively) (Fig. 9D). However,
comparisons between the solubilisation proles obtained for
MCT® in MIF PO4 and MIF cit. over this period showed little
deviation from one another (P ¼ 0.58).
Cellular uptake.MCT® crystals produced a clear birefringent
signal under polarised light, which assisted in the identication
of both extracellular and intracellular adjuvant deposits
(Fig. 10). Incidences of the latter were minimal as was the
degree of cytoplasmic loading encountered i.e. one particulate
per cell (Fig. 10B and C). Internalised particles were predomi-
nantly smaller than their extracellular counterparts, although
particles as large as ca. 20 mm were viewed in the intracellular
environment. Partial phagocytosis of larger structures (>20 mm),
promoted through cellular interaction with needle tips was also
observed (Fig. 10B).RSC Adv., 2019, 9, 24505–24518 | 24511
Fig. 7 Particle size distributions of MCT® in saline (0.7 mg mL1), plus
OVA (0.7 mgmL1 + 70 mgmL1) and R10medium (2 mgmL1). Purple
boxes represent the interquartile range of the data while blue lines
show the median particle size. Blue dotted lines represent the minima
and maxima of the data obtained. Panels (A) and (B) represent the
distributions for the length and width of MCT® particles respectively.
Distributions were analysed for statistical signiﬁcance using a Kolmo-
gorov–Smirnov test.
Fig. 8 Zeta potential measurements of MCT® alone (0.7 mg mL1)
and MCT® + OVA (0.7 mg mL1 + 70 mg mL1) in saline. Error bars are
representative of SD of the measurement where n ¼ 5. Data were
analysed for statistical signiﬁcance using a two-tailed unpaired T-test.
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View Article OnlineCell viability. The absorbance values obtained from control
wells, which contained no cells + MCT®, became more prom-
inent as the concentration of the adjuvant was increased,
illustrating that higher concentrations of this material had the
potential to interfere with the results of the assay (data not
shown). However, background correction at 600 nm was suﬃ-
cient to negate contributions from both residual adjuvant
deposits and cellular debris. MCT® at concentrations up to
2 mg mL1 did not adversely inuence the viability of THP-1
diﬀerentiated macrophages relative to that observed for
untreated controls (>95% viability, P > 0.9) (Fig. 11).
Discussion
Vaccinological advances, including the development of safer
and more eﬀective immunopotentiating compounds, are24512 | RSC Adv., 2019, 9, 24505–24518heavily reliant on the exposition of structure-activity relation-
ships (SARs) such as those proposed herein for MCT®.
Furthermore, this is the rst study to demonstrate that the
physicochemical properties of MCT®, play a pivotal role in the
immunological processing of this adjuvant by APCs.
The IR vibrations acquired for MCT® conrmed its identity
as L-tyr, revealing the presence of both structural amino and
phenolic functional groups. While DFT calculations also pre-
dicted additional contributions from phenolic hydroxyl and
carboxylic carbonyl groups around 3600 & 1750 cm1 respec-
tively,52,53 these bands were neither detected in this study or
observed by others experimentally for L-tyr in its solid state.53–55
In this phase, L-tyr is reported to exist in a exible zwitterionic
conguration,53,56 the structure of which is stabilised through
intermolecular hydrogen bonding.57 Yadav et al. proposed that
the presence of such species could be identied by the presence
of a spectral combination band at ca. 2075 cm1.53 Indeed, both
MCT® and L-tyr yielded evidence of this band around 2077 cm1
inferring that both samples had near identical molecular
congurations.
L-tyr crystals are populated by geometrically orthorhombic
unit cells, which are preferentially elongated in the direction of
the b axis.57 XRD analysis revealed that MCT® possessed a high
degree of structural order and that reection positioning was
akin to that of L-tyr; however, unit cell parameters for both
samples were not explicitly calculated herein. The resultant
crystals congregated to form extensive rod-like projections,
which were large and heterogeneous in length via TEM. MCT®
also appeared to lack a water decomposition phase by TGA
(<200 C), which indicated the lack of physically adsorbed
moisture at the surface interface. A decrease in hydroxyl display/
surface functionality has been associated with the reduced
reactivity of aluminium salts in vitro in terms of pro-
inammatory cytokine production, ROS generation and
inammasome activation.58 The depletion of IgE titres in vivo
has also been reported following vaccination with highly crys-
talline materials,58 a mechanism which has been tentativelyThis journal is © The Royal Society of Chemistry 2019
Fig. 9 Solubility proﬁles of MCT® vaccines in MIF over a period of 168 h at 37 C, pH 7.4  0.05. Panel (A) shows the solubility of MCT® in MIF
base (purple lines) while panels (B) and (C) highlight its solubility in MIF phosphate and MIF citrate respectively (blue and green lines respectively).
Panel (D) compares the initial rate of solubilisation of MCT® in the various formulations of MIF using a linear regression analysis. Error bars are
representative of SD of the measurement where n ¼ 5. Data were analysed for statistical signiﬁcance using a Friedman test followed by Dunn
post hoc tests.
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View Article Onlinelinked to the suppression of IL-18 secretion.47 While further
studies are required in order to fully validate these supposi-
tions, these SARs may provide an initial explanation regarding
the ability of MCT® to promote the class-switch recombination
mechanisms required to ameliorate allergic responses whilst
minimising local side-eﬀects following administration.
One documented advantage of MCT® in SCIT as oppose to
traditional aluminium salts is its rapid relative elimination
from the site of injection via the bloodstream, typically within
one week of administration.33 The solubility of MCT® in model
interstitial uid was between 0.36–0.4 mg mL1 and its rate of
dissolution was predominantly volume dependent, as evi-
denced by the consistency of values obtained per time point.
While these values are marginally lower than the documented
solubility of L-tyr in aqueous solution (0.45 mg mL1)59
increasing the ionic strength of the surrounding environment
has been shown to decrease the solubility of this amino acid.60
The solubility of MCT® was also moderately increased in the
presence of phosphate and citrate ions; however, due to meth-
odological constraints, contributions from serum proteins were
not considered in this study. Such contributions are of partic-
ular importance with regards to the formation of proteinaceous
coronas, which may provide some protection against ligand-
induced solubility in vivo. This may be benecial with regards
to the conservation of the adjuvant depot, increasing the
amount of material available to interact with inltrating gran-
ulocytes and APCs, the recruitment of which has been observed
as early as 4 h post immunisation with MCT®-adjuvantedThis journal is © The Royal Society of Chemistry 2019vaccines.61 Furthermore, an increase in cell-mediated trans-
location of antigen/antigen–adjuvant complexes to lymph
nodes may serve to facilitate vaccine priming, an essential pre-
requisite for the development of robust adaptive immune
responses.62
The hydrodynamic size of particles within the adjuvant bolus
directly inuences the rate at which they are removed from the
injection site by inltrating phagocytes, with particles between
1–3 mm in size being considered optimal for recognition and
engulfment by macrophages.63–65 Within saline the proportion
of particles approximately corresponding to this range (0.1–5
mm) was consistently minimal (max. 79.3 mg mL1 L-tyr) and the
addition of model antigen resulted in a near complete abolition
of this population. These observations indicate that the abun-
dance of particulates within this range was somewhat inde-
pendent of adjuvant concentration but was signicantly
decreased in the presence of small amounts of antigen;
however, whether such correlations exist for particles exceeding
5 mm is currently unclear without the use of sizing methodol-
ogies with both greater resolution and upper limits of detection.
Furthermore, the large hydrodynamic length of MCT® crystals
in biological medium (>ca. 10 mm) appeared to partially stymie
the scavenging capacity of THP-1 macrophages in vitro, as
demonstrated by the limited incidence of crystals located
within the cytoplasm of these model phagocytes following brief
exposure. This is in stark contrast to results obtained using
a crystalline aluminium adjuvant (Fig. S3†) where it's optimal
particle size (median size – 1.4 mm (Fig. S2†)) appeared toRSC Adv., 2019, 9, 24505–24518 | 24513
Fig. 10 Light images of native THP-1 diﬀerentiatedmacrophages in R10medium ((A), mag. 400, scale bar 50 mm) and those treatedwith MCT®
(2 mgmL1) for 1 h (B and C). Images (B) and (C) were taken under polarised light at a magniﬁcation of 200 and 400 respectively (scale bars 100
and 50 mm respectively). The cells used as inserts are identiﬁed by a black asterisk. Those highlighted by red and black asterisks in panels B & C
appear to demonstrate some element of adjuvant loading.
Fig. 11 Viability of THP-1 diﬀerentiated macrophages in the presence
of various concentrations (0.3–2 mg mL1) of MCT® after 24 h
incubation at 37 C. Cell viability was measured using the Presto blue
assay at a wavelength of 570 nm. Error bars represent the SD of the
measurement where n ¼ 4. Data were analysed for statistical signiﬁ-
cance using an ANOVA followed by Tukey post hoc tests.
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View Article Onlinefacilitate cytoplasmic loading to the point of near saturation in
the majority of cells over the same period of incubation
(Fig. S4†). Such observations emphasise that size-related24514 | RSC Adv., 2019, 9, 24505–24518parameters present a signicant impediment with regards to
the aggregate cellular recognition and uptake of MCT® under in
vitro conditions.
However, despite these obvious limitations, perpendicular
contact with needle peripheries, whose dimensions were
substantially smaller (median width – 2.8 mm), appeared to
result in both partial and complete phagocytosis of adjuvant
material, although further investigations are required in order
to unequivocally conrm this. Such events did not induce any
signicant changes in the metabolic activity of macrophages
conrming that these interactions did not adversely inuence
cell viability at the concentrations studied herein. This
prospective mechanism of uptake is consistent with that
observed for ellipsoidal particles, where the kinetics and
success of internalisation showed a greater dependency upon
the eccentricity of the contact site than particulate volume.66,67
Interestingly, microscopic and ELS analysis indicated that
a small amount of antigenic adsorption also preferentially
occurred at these sites (Fig. S1†) irrespective of the negative zeta
potential values obtained for both OVA and MCT®. However,
the binding capacity and aﬃnity of antigens for these particular
sites does require further investigation before denitive
conclusions can be drawn. Nevertheless, it is highly probable
that the terminals of MCT® crystals act as a scaﬀold for the
direct presentation of antigen to APCs. These observations inferThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinethat MCT® may play an active role in the enhancement of MHC
class II expression and prevention of proteolytic degradation in
the lysosomal compartment, both of which have been shown to
improve the immunogenicity of vaccine formulations in
vivo.42,46,68
As mentioned previously, the negative zeta potential of
MCT® limited the interfacial adsorption of a model antigen
bearing the same charge i.e. OVA. Negatively charged adjuvants
have been routinely employed to attenuate the aﬃnity of
antigen–adjuvant complexes through electrostatic mecha-
nisms, which serves to induce a more robust immunological
response post immunisation.69–73 However, it is debatable how
useful this would be specically in the case of SCIT, where the
success of individual treatments appears to be somewhat
dependent upon the prolonged retention and gradual release of
allergens at the site of injection.35 Heightened retention of
weakly associated antigens is possible, however, through the
entrapment of these proteinaceous species within adjuvant void
spaces.73 This mechanism combined with the sparing solubility
of MCT® at the injection site may provide a convincing expla-
nation as to how this adjuvant can act as an antigen depot in
formulations possessing low adsorption coeﬃcients.
While the inuence of adjuvant zeta potential upon the
adsorption of proteins within biological uid remains equiv-
ocal, anionic particles have been shown to be more eﬀectively
opsonised through the adsorption of serum immunoglobu-
lins.74 Such events have been shown to increase the internal-
isation but not the recognition of micron-sized entities by
macrophages in vitro through FcR-mediated phagocytosis.75
However, the study concluded that these trends were not
applicable to larger particles.75 It is therefore unlikely that
opsonisation could enhance the uptake of MCT® in vivo.Conclusions
This study has revealed that the physicochemical properties of
MCT® contribute to the recognition of this material by APCs in
vitro. While these data are preliminary in nature, the substantial
size of crystallites appeared to be a limiting factor with regards
to their recognition and uptake by THP-1 macrophages, at least
following short term exposure. However, it is plausible that the
solubility of MCT® in interstitial uid will facilitate a gradual
decrease in the size of adjuvant particles and thus increase the
likelihood of particulate recognition by inltrating immune
cells. Such observations imply that the therapeutic modus
operandi of MCT® may involve some element of direct antigen
presentation to APCs and cell-mediated migration to the
draining lymph nodes, although conrmation of this requires
further investigation. In conjunction, these mechanisms may
serve to explain howMCT® potentiates a robust immunological
response in SCIT despite exhibiting a theoretically low reactivity
in situ.Funding
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